PGR and cancer: Importantly, PBF and Src were most highly expressed in the more aggressive HER2-positive (ER−/PR−/HER2+) and TNBC (ER−/PR−/HER2−) tumours, which were associated with a significantly lower DFS compared with the ER+ and/or PR+ luminal cancers (Supplementary Fig. 8A).